Engflag

Polivy

Quick links to important sections

Polivy

Polivy_LV

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Polivy

Quick Facts

Property Description
Active ingredient Polatuzumab vedotin
Form Lyophilized powder for intravenous infusion
Pharmacological class Antibody-Drug Conjugate (ADC); Antineoplastic agent
Target CD79b protein on B-cells
Origin Humanized monoclonal antibody plus synthetic toxin

Polivy: Definition and Pharmaceutical Classification

Polivy is the prescription-only brand name for the active ingredient polatuzumab vedotin, which is classified as an advanced, first-in-class Antibody-Drug Conjugate (ADC) and a high-level antineoplastic agent (anti-cancer drug). This medicine is a form of targeted therapy that combines the specificity of an antibody with the cell-killing power of a cytotoxic drug. The structure of Polatuzumab vedotin confirms its dual origin/type as a biologic component—a humanized monoclonal antibody—chemically linked to a synthetic payload.

Composition and Physical Form of Polatuzumab Vedotin

Polatuzumab vedotin is structurally composed of three essential parts: the targeting antibody, a potent cellular toxin, and a cleavable linker that holds them together. The targeting portion is the Polatuzumab antibody, engineered to specifically bind to the CD79b protein found on the surface of B-cells, including malignant ones. The cytotoxic payload is Monomethyl auristatin E (MMAE), an anti-mitotic agent designed to halt cell division. The medicine is supplied as a lyophilized powder for solution for infusion in a single-dose vial and is administered via intravenous (IV) infusion by a healthcare professional. The inclusion of the vedotin payload and specialized linker is a distinguishing feature of this innovative ADC platform.

Targeted Purpose and General Benefit

The general therapeutic purpose of this medicine is to promote the highly specific and targeted destruction of malignant B-cells, a strategy clinically recognized for its potential in treating certain aggressive lymphomas. The drug is a CD79b-directed agent; upon binding, it is internalized by the target cell, where the chemical linker is cleaved to release the toxic MMAE payload inside. This focused mechanism interrupts the malignant cell's ability to proliferate and ultimately triggers its death. This targeted approach is intended to reduce the cancerous cell population while minimizing the systemic exposure to the cytotoxic agent compared to non-targeted systemic treatments, which provides the key general benefit of the Polatuzumab vedotin platform.

Regulatory References

  1. Polivy | European Medicines Agency (EMA)

What side effects are possible with Polivy?

The possible side effects and safety characteristics of polatuzumab vedotin (Polivy) are formally documented across several regulatory categories, based on official prescribing information.

Adverse Reaction Scope

Adverse reactions are broadly classified according to the affected System-Organ Class (SOC) and their frequency observed in clinical study populations. Safety concerns commonly fall under Blood and Lymphatic System Disorders, Nervous System Disorders, and Infections and Infestations.

Classification Representative Adverse Reactions
Very Common (ge 10%) Myelosuppression (Neutropenia, Anemia), Peripheral Neuropathy, Fatigue, Diarrhea, Nausea, Pyrexia.
Common (1% to < 10%) Pneumonia, Infusion-Related Reactions (IRRs), Vomiting, Constipation, Alopecia (Hair Loss).

Serious Adverse Reactions and Safety Constraints

The medicine is associated with risks designated as serious in regulatory documents. These include severe or fatal Myelosuppression and Serious and Opportunistic Infections, such as the rare but severe risk of Progressive Multifocal Leukoencephalopathy (PML). Other serious reactions noted are Tumor Lysis Syndrome (TLS) and Hepatotoxicity (liver injury).

Peripheral Neuropathy is specifically documented as a cumulative toxicity that can emerge as early as the first treatment cycle. Infusion-Related Reactions may occur as a delayed event up to 24 hours following administration.

For specific populations, official labeling advises that use in patients with moderate or severe hepatic impairment should be avoided. Additionally, the drug is classified as having a risk of Embryo-Fetal Toxicity, which necessitates specific precautionary measures for patients of reproductive potential.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory profile for Polivy (polatuzumab vedotin) addresses overexposure by outlining mandatory management steps for acute, severe toxicities that would be the primary consequence of overdose, as no specific acute overdose syndrome is defined.

Overdose Scope

Category Official Regulatory Statement
Documented overdose presentations Managed as the occurrence of severe, high-grade toxicities: Life-threatening reactions, Grade 4 Peripheral Neuropathy, and severe Infusion-Related Reactions (IRRs). Acute signs can include fever, chills, hypotension, and dyspnea [Source 1.4, 2.6].
Physiological systems affected Hematological (severe Neutropenia or Thrombocytopenia), Nervous (severe Peripheral Neuropathy), and Immune (severe IRRs) [Source 1.1, 3.1].
Population-specific overdose notes Administration should be avoided in patients with moderate or severe hepatic impairment due to the increased risk of toxicity [Source 3.1].

Emergency-Response Statements

Category Action Mandated by Regulatory Documents
When medical help is required Patients must tell their doctor or nurse immediately if they experience any severe side effects after administration [Source 2.1]. Urgent intervention is required for a life-threatening reaction [Source 1.2].
Mandated actions (Acute) Polivy must be discontinued immediately and permanently for a life-threatening reaction or Grade 4 Peripheral Neuropathy [Source 1.2, 3.2]. Infusion interruption and supportive treatment are required for IRRs [Source 1.5].
Antidote Information No specific antidote is listed in the regulatory prescribing information.

Connection to the Overall Overdose Profile

The official documents define the approach to overexposure by mandating the immediate and permanent cessation of the medicine for the most severe, life-threatening adverse events [Source 1.2]. The management of this condition is focused on providing supportive treatment and close monitoring for severe hematological or neurological toxicity, rather than following a specific set of poisoning protocols [Source 1.5, 3.1].

Therapeutic Uses of Polivy

What Polivy Treats: Main Uses and Benefits

Polivy is commonly used for Diffuse Large B-Cell Lymphoma (DLBCL), a condition marked by increased physiological stress, in both newly diagnosed adult patients and those with recurrent or episodic manifestations. This treatment is applied in clinical settings that involve acute or unstable symptom patterns. The treatment is used for managing conditions where a primary objective is addressing the tumor burden and supports the patient during difficult episodes by easing distress.

This medicine helps address symptom clusters related to systemic imbalance, such as symptoms that create noticeable physiological strain like persistent fever, night sweats, and unplanned weight loss. The treatment is relevant for easing symptoms related to physical discomfort, which includes manifestations like enlarged lymph nodes and internal masses. This process supports general well-being during symptomatic phases by contributing to easing the overall symptom load.

Quick Fact: Supportive Symptom Management

Polivy is commonly used for managing conditions that present with aggressive B-cell lymphoma, where the goal is to ease the burden of systemic indicators and physical mass effects, supporting day-to-day comfort during symptomatic periods.

Eligibility and Restrictions for Use

Eligibility to Use Polivy

Polivy is authorized for use only in adult patients aged 18 years and older who have been diagnosed with the specific forms of Diffuse Large B-cell Lymphoma (DLBCL) or High-Grade B-cell Lymphoma (HGBL) for which the medicine is approved. The safety and effectiveness of Polivy have not been established in the pediatric population (under 18 years) due to a lack of sufficient clinical data.

Restrictions and Non-Eligibility

Regulatory guidelines state that Polivy should not be administered if a patient currently has an active severe infection. Furthermore, use should be avoided in patients with moderate or severe hepatic impairment. Treatment is restricted for individuals with severe renal impairment (creatinine clearance < 30 mL/ min), as an official dose has not been determined for this patient group.

Polivy is not recommended during pregnancy due to the potential for fetal harm; therefore, effective contraception is required for both male and female patients during and after therapy. Women are also advised not to breastfeed during treatment and for a period after the final dose. Patients with pre-existing peripheral neuropathy are eligible but require strict clinical oversight.

What should I know about interactions with other medicines?

The official regulatory profile for Polivy strictly defines interactions based on the clearance of its active cytotoxic component, unconjugated Monomethyl auristatin E (MMAE). This component is a documented substrate of the hepatic enzyme CYP3A4 and the efflux transporter P-glycoprotein (P-gp). These documented interactions establish specific constraints for co-administration.

Interaction Category Official Regulatory Statement
Metabolic Impact The MMAE component is a substrate of the hepatic enzyme CYP3A4 and the efflux transporter P-glycoprotein (P-gp).
Exposure Modifiers Co-administration with Strong CYP3A Inhibitors may increase the unconjugated MMAE exposure, potentially increasing toxicities. Co-administration with Strong CYP3A Inducers may decrease the unconjugated MMAE exposure.
Vaccine Restriction Live or live-attenuated vaccines should not be given concurrently with Polivy treatment.
Administration Constraint The product must not be mixed with or administered as an infusion with other drugs and requires a dedicated infusion line.
Population Restriction Administration in patients with moderate or severe hepatic impairment (bilirubin > 1.5 imes ULN) should be avoided due to the formally documented potential for increased MMAE exposure.

The interaction structure is defined by the drug’s metabolic dependence on the CYP3A4 pathway, leading to necessary restrictions on concurrent strong enzyme modifiers. The restriction against use in moderate to severe hepatic impairment is officially documented by regulatory agencies due to the increased risk of systemic exposure to the unconjugated MMAE component.

Mechanism of Action

Targeted Recognition and Delivery via CD79b

Polivy's mechanism initiates with the precise binding of its antibody component, Polatuzumab, to the CD79b protein on the cell surface. This binding initiates receptor-mediated endocytosis, internalizing the entire Antibody-Drug Conjugate (ADC) into the target cell. This highly specific action engages mechanisms that regulate cell survival and proliferation.

Intracellular Activation and Cell Cycle Disruption

Once internalized, the drug travels to the cell’s lysosome, where specific proteases (enzymes) cleave the chemical linker, releasing the active payload, Monomethyl auristatin E (MMAE), into the cytoplasm. MMAE then targets tubulin, inhibiting its polymerization into microtubules. This mechanism modifies early molecular steps that result in sustained mitotic arrest at the G2/M checkpoint. This process induces apoptosis (programmed cell death) and contributes to the clearance of the targeted cell population.

Dosage and Administration Information

How to Use Polivy: Official Administration Guidelines

Polatuzumab vedotin (Polivy) is administered according to a strict, standardized protocol based on prescribing information. Its use is defined by a fixed administration route, a body-weight-based dosing formula, and a specific cyclic schedule, ensuring standardized use in clinical settings.

Administration Scope

Feature Official Instruction
Route of Administration Must be given exclusively as an Intravenous (IV) infusion; it is not for IV push or bolus administration.
Dosing Schedule The standard starting dose is 1.8 mg/kg body weight. Dosing must not exceed 240 mg per cycle and includes mandatory reduction steps to 1.4 mg/kg and 1.0 mg/kg.
Frequency and Duration Administered once every 21 days (Day 1 of the cycle) for a total, fixed course of 6 cycles.
Special Conditions Must be used in combination with specific chemotherapy and biologic agents (e.g., R-CHP or BR regimens).

Procedural Administration Rules

Administration involves precise procedural steps that define the physical act of usage:

  • Premedication with an antihistamine and antipyretic must be given at least 30 minutes prior to the infusion.
  • The lyophilized powder requires reconstitution and dilution using specific diluents (e.g., 0.9% Sodium Chloride) to a final concentration between 0.72 and 2.7 mg/mL.
  • The first infusion is administered over 90 minutes, which may be reduced to 30 minutes for subsequent doses if the initial infusion is tolerated.
  • The medicine must be administered through a dedicated infusion line equipped with a sterile 0.2 or 0.22 micrometer filter.
  • Missed Doses should be administered as soon as possible, with the subsequent schedule adjusted to maintain the 21-day interval.

This structured use protocol, including the fixed 6-cycle duration and the required combination use, defines the standardized procedural framework for Polivy's application.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Polivy

This section provides an overview of the types of research studies that have been conducted for Polatuzumab Vedotin, detailing what the researchers examined and what is still being studied, based on official regulatory sources and scientific literature. This is not medical advice or a guide to treatment.

Evidence for Use in Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Research for this use was studied for primarily based on a large, international Phase 3 Randomized Controlled Trial (RCT). This research was evaluated in adults with previously untreated DLBCL. The main focus of this research was observed in tracking the time until the disease worsened, returned, or death occurred, which is known as Progression-Free Survival (PFS). Studies were designed to measure outcomes such as PFS and Overall Survival (OS).

The primary analysis of the trial focused on measurements for the PFS endpoint, but measurements of the OS endpoint were observed to have no statistically significant difference between the two arms in the main report. Long-term effects are not fully established, and follow-up is ongoing to gather more complete survival data. The results apply only to the populations studied, and data for certain groups remain insufficient.

Evidence for Use in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

The initial research supporting this use was observed in a smaller, randomized Phase 2 Trial. This research was evaluated in adult patients, many of whom were older and considered ineligible for high-intensity procedures, and who had received at least two prior treatment regimens. The main outcomes research examined were the rate of Complete Response (disappearance of measurable disease signs) and the duration of that response. Findings describe patterns observed in these outcomes for patients in this heavily pretreated group.

Because the pivotal trial for this indication used a relatively small sample size of patients, regulatory approval was granted based on a smaller study, indicating that data are still emerging. The results apply primarily to the specific patients included in the study. Subsequent observational studies examining real-world settings contribute to understanding symptom patterns in populations that were often more complex than those included in the pivotal trials.

Frequently Asked Questions (FAQ)

Common questions about Polivy (FAQ)

Q: Is Polivy considered a chemotherapy drug?

A: Polivy is classified as an Antibody-Drug Conjugate (ADC), which is a type of targeted therapy. It links a monoclonal antibody, which is a biologic agent, directly to a potent cytotoxic agent (MMAE) that kills cancer cells. This cytotoxic agent's function is often associated with traditional chemotherapy drugs, but Polivy delivers the payload in a more targeted way.

Q: Do side effects from Polivy usually go away after treatment stops?

A: Recovery from side effects varies depending on the specific adverse event. For instance, official regulatory documents indicate that the most common type of nerve damage (peripheral neuropathy) improved or resolved for many patients in clinical studies. This resolution often occurred after a median of 1 to 4 months following the symptom's onset. Concerns about the duration of side effects are typically addressed by the patient's healthcare team.

Q: Are there any long-term side effects associated with Polivy?

A: Official product information notes that peripheral neuropathy is a cumulative toxicity, which means the risk may increase over the course of treatment. Furthermore, the label highlights the potential for rare but serious adverse events such as Progressive Multifocal Leukoencephalopathy (PML), which is a severe brain infection. Long-term health is typically assessed by healthcare providers during and following treatment.

Q: What should I watch out for with Polivy treatment?

A: Official safety information advises that patients be aware of specific signs of potential complications. These may include symptoms of infusion-related reactions (like fever, chills, or a rash), indications of a serious infection (such as fever or persistent cough), and signs of liver problems (including severe tiredness, dark urine, or yellowing of the skin). Reporting any new or worsening symptoms to the treating physician is standard care.

Q: Are headaches a sign of a serious side effect from Polivy?

A: Headaches have been reported as a common side effect in patients receiving this treatment. However, in the official safety documents, headaches are not listed as a primary, defining symptom of the most serious adverse events, such as Tumor Lysis Syndrome or severe liver injury. A severe or persistent headache should be reported to the patient's healthcare team.

Q: What kind of infections are common when taking Polivy?

A: Because Polivy can affect the immune system, regulatory documents note that patients may have an increased risk of infection. Common infections reported in clinical studies include pneumonia, various herpes virus infections, and infections of the upper respiratory tract. Regulatory documents classify the risk of infection as serious, which means patients are typically monitored closely by their healthcare team.

Q: Does Polivy interact with common pain relievers like Tylenol or Advil?

A: Official information states that the drug's active payload is broken down by the CYP3A4 enzyme in the liver. Drug interaction warnings focus on avoiding strong inhibitors or inducers of this enzyme. The label does not specifically address common pain relievers like Tylenol (acetaminophen) or Advil (ibuprofen) by name, but it is important that patients inform their provider about all concomitant medications being taken.

Q: What kind of vitamins or supplements should I avoid while on Polivy?

A: The metabolism of the active drug component involves the CYP3A4 enzyme system. Therefore, regulatory warnings advise caution regarding any vitamins, herbal remedies, or supplements that are known to act as strong inhibitors or inducers of this enzyme. Patients are typically expected to provide their complete list of supplements to their healthcare team for review.

Q: Does Polivy treatment affect fertility?

A: Based on its mechanism of action and information from non-clinical studies, Polivy may have the potential to impair fertility in both male and female patients. For this reason, official regulatory labeling specifies that effective contraception is required for both men and women during treatment and for a period after the final dose.

Q: What is the percentage success rate mentioned in the Polivy studies?

A: Official clinical trial results are often reported using endpoints that measure effectiveness, such as Progression-Free Survival (PFS), Overall Survival (OS), and Complete Response (CR) rate. Regulatory documents describe specific quantitative results for these endpoints, which can be reviewed in the clinical study summaries of the official product label.

Q: What is the 'Pola-R-CHP' regimen I see mentioned online?

A: The 'Pola-R-CHP' regimen refers to the combination of Polivy with several other agents that are approved for the treatment of previously untreated Diffuse Large B-cell Lymphoma (DLBCL). These agents are a rituximab product, cyclophosphamide, doxorubicin, and prednisone.

Q: How is Polivy administered—through a central line or regular IV?

A: Polivy is administered exclusively as an intravenous (IV) infusion through a dedicated infusion line that includes a sterile filter. The official instructions require a dedicated line but do not mandate a specific type of intravenous access, such as a central line or a regular peripheral IV, for all patients.

Q: Does taking Polivy require frequent blood tests?

A: Yes, regulatory documents advise that complete blood counts must be monitored before each dose of Polivy. This monitoring is necessary because of the documented risk of myelosuppression, which involves severe reductions in blood cell counts (like white blood cells, red blood cells, and platelets).

Q: Why do doctors check for Hepatitis B before starting Polivy?

A: The official product information advises evaluation and careful monitoring for patients who are at risk of Hepatitis B Virus (HBV) reactivation. This precaution is noted because this type of treatment can potentially increase the risk of serious infections, including the possibility of a dormant virus like Hepatitis B becoming active again.

Q: Is Polivy a type of immunotherapy?

A: Polivy is classified as an Antibody-Drug Conjugate (ADC) and a form of targeted therapy. Since it utilizes a monoclonal antibody, a biologic agent designed to specifically target a protein on cancer cells, its mechanism is related to the broader class of medicines often referred to as immunotherapy.

Q: What are the signs of an infusion-related reaction to Polivy?

A: Signs of an infusion-related reaction can occur during the infusion or up to 24 hours afterward. These signs may include fever, chills, rash, breathing problems, low blood pressure, or hives. Official safety information indicates that patients should be monitored closely during and after the infusion.

Q: Why do they give steroids with Polivy?

A: Steroids, such as prednisone, are typically given as part of the combination regimen (e.g., R-CHP) that is required when administering Polivy for previously untreated DLBCL. The steroid is an active part of the regimen used to treat the lymphoma, and it is not specifically listed as a premedication for the Polivy infusion itself.

Q: Is Polivy used to treat Hodgkin's lymphoma?

A: According to official regulatory indications, Polivy is authorized for use only in specific types of Diffuse Large B-cell Lymphoma (DLBCL) or High-Grade B-cell Lymphoma (HGBL). It does not carry an indication for the treatment of Hodgkin's lymphoma.

Q: Will I need to stay overnight at the hospital for Polivy infusions?

A: Polivy infusions are typically performed in an outpatient setting. Official instructions require that patients be monitored for at least 90 minutes following the initial infusion and for at least 30 minutes following all subsequent infusions. An overnight stay is not part of the standard procedural protocol.

How should Polivy be stored and disposed of?

Polivy (polatuzumab vedotin-piiq) Storage and Disposal

Unreconstituted Vials: Polivy vials must be stored in a refrigerator at 2 C to 8 C (36 F to 46 F) and kept in the original carton to protect from light. The vials and prepared solutions must not be frozen or shaken.

Stability and Time Limits: The reconstituted solution must be diluted within a maximum of 48 hours when refrigerated, or within 8 hours at room temperature. The total storage time for the final diluted solution depends on the diluent used and must not exceed specified limits.

Disposal and Handling: Polivy is classified as a cytotoxic and hazardous drug. Follow applicable special handling and disposal procedures for cytotoxic waste. Any unused product or waste material must be disposed of according to institutional and local requirements. Keep this medicine out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Polivy found in:

A-Z Index: